NeuroFrontiers

Could an oral compound represent a new class of psychotropic agent with a non-D2-receptor binding mechanism of action for the treatment of psychosis in schizophrenia? That’s what the authors of a recent study wanted to find out, and it’s what Dr. Matt Birnholz explores in this Audio Abstract.

To review the full abstract, please click here.

The current therapies we have available for schizophrenia are very effective at reducing psychotic symptoms in most patients, but for about 30 percent of patients, adverse events and suboptimal treatment responses can take a heavy toll. Could emerging therapies help us address these unmet needs? Learn more about the efficacy and tolerability limitations of current treatment options and what’s on the horizon with Dr. Charles Turck and Dr. Philip Harvey from the University of Miami Miller School of Medicine.

If clinicians can better understand the pathophysiology of schizophrenia, it could lead to more therapeutic options for this illness. So which potential mechanisms could be involved in its pathophysiology and in the discovery of more treatments for schizophrenia? Learn more about this illness with Dr. Jose Rubio, Assistant Professor at the Institute for Behavioral Science at the Feinstein Institutes for Medical Research.

Meet Susan and Mary, two real-world patients with different manifestations of progression in their RMS who were treated with the therapy option MAYZENT. So why was MAYZENT the appropriate choice for these patients, and how did they get started on this treatment option? Here to walk us through these two real-world patient cases and their perspectives on RMS management are Dr. Brian Barry and Dr. Amos Katz.

Eye movement desensitization and reprocessing (EMDR) therapy is an interactive psychotherapy used to relieve stress and reduce symptoms of trauma. It is most commonly associated with the treatment of posttraumatic stress disorder (PTSD). But can this therapy also treat other stress-related disorders? To go into further detail, Dr. Charles Turck is joined by Dr. Deborah Korn, a clinical psychologist in private practice in Cambridge, Massachusetts and co-author of the book titled Every Memory Deserves Respect: EMDR, the Proven Trauma Therapy with the Power to Heal.

The STING protein is a novel treatment pathway for cancer. How might it affect our patients’ immune response to diseases such as brain cancer? Dr. Sean Lawler, an Associate Professor in the Department of Pathology and Laboratory Medicine at Brown University in Providence, Rhode Island. joins Dr. Andrew Wilner to explore the role of the STING pathway.

Brain metastases are common in patients with advanced melanoma and are a leading cause of cancer-related death. However, little is known as to why melanoma spreads to the brain, but new research from Columbia University may provide some answers. To discuss this recent discovery, Dr. Andrew Wilner is joined by Dr. Benjamin Izar, Assistant Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons.

Curious about how the 2022 Psych Congress came together? Tune in to hear Steering Committee member Dr. Craig Chepke give us a behind-the-scenes look at the conference. Dr. Chepke is also the Medical Director of Excel Psychiatric Associates.

Prosopagnosia, also known as face blindness, is a rare cognitive disorder. Joining Dr. Andrew Wilner to share his insights on this condition is Dr. Jason Barton, a Professor of Neurology, Ophthalmology and Visual Sciences, and Psychology at the University of British Columbia in Vancouver, Canada.

Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy. Due to recent research from Florida State University, we might have a better understanding of the potential link between a specific protein and increased vulnerability to neurodegeneration among patients with this disorder. Dr. Andrew Wilner is joined by Dr. Sanjay Kumar, Professor of Biomedical Sciences and Neuroscience at Florida State University, to discuss this new discovery.